title: Using daily interactive voice response assessments: to measure onset of symptom improvement with duloxetine.
abstract: Most clinical trials measure patient responses weekly, requiring patients to accurately recall and report their symptoms from the previous six days. More frequent assessments would be less susceptible to recall errors and recency effects as weekly assessments, but increased office visits burden clinicians and patients and can lead to higher attrition or non compliance. Interactive voice response (IVR) technology permits data collection at greater frequencies with minimal reporting burdens. An ancillary study within a randomized clinical trial evaluated the use of IVR to gather measures of patients' ratings of emotional and painful symptoms of depression on a daily basis. Unmedicated patients randomized to a starting dose of duloxetine of 30 mg QD (n=67) or 60 mg QD (n=70) called an IVR system daily to complete Verbal Numeric Scales for pain and Patient Global Impression of Improvement for both physical and emotional changes. Patients' compliance with daily IVR assessments was examined, and the IVR data obtained showed that patients started at 60 mg reported less pain and greater physical and emotional improvements than patients started at 30 mg. Dose related differences were evident as early as one day after the start treatment. This study provides new data about the usefulness of daily IVR assessments in clinical research and supports other studies regarding early symptom improvement with duloxetine.
authors.affiliation: Healthcare Technology Systems, Inc., Madison, Wisconsin, USA. hmoore@healthtechsys.com
authors.forename: Heidi K
authors.initials: HK
authors.lastname: Moore
authors.forename: Madelaine M
authors.initials: MM
authors.lastname: Wohlreich
authors.forename: Michael G
authors.initials: MG
authors.lastname: Wilson
authors.forename: James C
authors.initials: JC
authors.lastname: Mundt
authors.forename: Maurizio
authors.initials: M
authors.lastname: Fava
authors.forename: Craig H
authors.initials: CH
authors.lastname: Mallinckrodt
authors.forename: John H
authors.initials: JH
authors.lastname: Greist
references.citation: J Clin Psychiatry. 2005 Feb;66(2):148-58
references.pmid: 15704999
references.citation: Arch Gen Psychiatry. 1984 Mar;41(3):238-45
references.pmid: 6367689
references.citation: J Clin Psychopharmacol. 2005 Dec;25(6):552-60
references.pmid: 16282837
references.citation: Arch Intern Med. 2001 Nov 12;161(20):2481-7
references.pmid: 11700161
references.citation: Biometrics. 1982 Dec;38(4):963-74
references.pmid: 7168798
references.citation: J Clin Psychiatry. 2001;62 Suppl 15:18-21
references.pmid: 11444762
references.citation: J Psychiatr Res. 2005 Mar;39(2):161-72
references.pmid: 15589564
references.citation: J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
references.pmid: 14399272
references.citation: Control Clin Trials. 2003 Apr;24(2):182-99
references.pmid: 12689739
references.citation: Prim Care Companion J Clin Psychiatry. 2003 Feb;5(1):19-28
references.pmid: 15156243
references.citation: J Clin Psychiatry. 2004 Apr;65(4):521-30
references.pmid: 15119915
references.citation: JAMA. 1997 Sep 17;278(11):905-10
references.pmid: 9302242
references.citation: Anesth Analg. 1998 Jan;86(1):102-6
references.pmid: 9428860
references.citation: Psychopharmacol Bull. 2002 Autumn;36(4):106-32
references.pmid: 12858150
references.citation: Sleep. 2003 Nov 1;26(7):793-9
references.pmid: 14655910
references.citation: Psychiatr Serv. 1997 May;48(5):611-2
references.pmid: 9144814
references.citation: Acad Emerg Med. 2003 Apr;10(4):390-2
references.pmid: 12670856
references.citation: J Clin Psychiatry. 2002 Apr;63(4):308-15
references.pmid: 12000204
references.citation: Br J Med Psychol. 1959;32(1):50-5
references.pmid: 13638508
references.citation: Biometrics. 1997 Sep;53(3):983-97
references.pmid: 9333350